menu

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

close
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

    Released May 18, 2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

    Released May 18, 2017

Facebook Comments

Programs 4/21/21